NCT02095548View on ClinicalTrials.gov

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Moderate to Severe Osteoarthritis
Interventions
DRUG

SM04690, 0.03mg/2mL

DRUG

SM04690, 0.07mg/2mL

DRUG

SM04690, 0.23mg/2mL

DRUG

Placebo

Trial Locations (7)

Unknown

Tucson

El Cajon

Walnut Creek

Miami

Boston

Duncansville

Dallas

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY

NCT02095548 - Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA) | Biotech Hunter | Biotech Hunter